What alternatives can be used for oral contrast for CT since Omnipaque oral is not available. What is data on using Gastrograffin and how would it be dosed for this indication

Comment by InpharmD Researcher

Alternatives to oral iohexol (Omnipaque) for CT include other water-soluble iodinated agents, such as iopamidol and diatrizoate meglumine/diatrizoate sodium (Gastrografin), as well as barium sulfate and neutral oral contrast agents, depending on the clinical indication. In a randomized trial of 100 adults undergoing abdominopelvic CT, diatrizoate and iohexol provided similar gastrointestinal opacification, although iohexol was rated more favorably for taste; the study was not designed to establish comparative safety. Per prescribing information, the usual adult Gastrografin dose for CT body imaging is 240 mL of solution prepared by diluting 25 mL in water to a total volume of 1 liter, administered orally approximately 15 to 30 minutes before imaging. Gastrografin’s hyperosmolarity may increase gastrointestinal fluid shifts and the risk of fluid or electrolyte disturbances, which should be considered when selecting an alternative.

Search included current guidelines, review articles, prescribing information, and primary studies evaluating oral contrast alternatives to iohexol for CT, with emphasis on Gastrografin efficacy, safety, and adult dosing

Background

According to the 2026 European Society of Urogenital Radiology (ESUR) Contrast Media Safety Committee guidelines, water-soluble iodinated contrast media are generally preferred for gastrointestinal opacification during computed tomography (CT). Oral agents include high-osmolality ionic contrast media, such as diatrizoate meglumine/sodium and ioxitalamate meglumine, and nonionic low- or iso-osmolality agents, including iohexol, iopamidol, ioversol, iopromide, iobitridol, and iodixanol. Dedicated, prediluted oral formulations of iohexol and iopamidol are available in selected markets. Nonionic low- and iso-osmolality agents are more palatable than high-osmolality ionic agents, and oral contrast use in abdominal CT has decreased. The most frequently reported adverse effects of oral iodinated contrast media are nausea, diarrhea, vomiting, and abdominal pain. Systemic absorption following gastrointestinal administration is approximately 1% to 2%, and hypersensitivity reactions are very rare. Pulmonary complications following aspiration of high-osmolality ionic agents are extremely rare. High-osmolality ionic agents may cause dehydration and hypovolemia in patients with fluid or electrolyte imbalances. Overall, the guidelines favor nonionic low- or iso-osmolality agents for oral administration based on palatability, while noting that contrast use in abdominal CT has declined. [1]

Several review articles describe barium sulfate, water-soluble iodinated contrast agents, and neutral oral contrast agents as alternatives for abdominal and pelvic CT, depending on the clinical indication. Barium sulfate may be considered for abdominal and pelvic CT but should be avoided when gastrointestinal perforation or leakage is suspected. Water-soluble iodinated agents, including diatrizoate meglumine/diatrizoate sodium (Gastrografin) and iopamidol, are additional alternatives. Neutral oral contrast agents, such as water, mannitol, and polyethylene glycol, are used for specific indications, including CT enterography and evaluation of inflammatory bowel disease. Oral contrast is not necessary for all abdominal CT examinations, and its use should be guided by the clinical indication. Positive oral contrast may be beneficial for evaluating suspected postoperative bowel leaks, fistulas, interloop abscesses, and selected oncologic indications; however, it should generally be avoided when evaluating suspected gastrointestinal bleeding because it may obscure active luminal contrast extravasation. It is also generally not indicated for hepatobiliary, pancreatic, or genitourinary imaging. Gastrografin is a water-soluble iodinated contrast agent that has been identified as an alternative to oral iohexol for abdominal and pelvic CT. However, Gastrografin is hyperosmolar and may cause greater gastrointestinal fluid shifts, nausea, diarrhea, and electrolyte abnormalities than low-osmolar agents such as iohexol. Aspiration is an additional safety concern with oral contrast administration. One review recommends a general target concentration of 13-15 mg iodine/mL for oral or rectal administration in adults, but this recommendation is not specific to Gastrografin. Overall, these reviews identify Gastrografin as an alternative but do not establish a specific Gastrografin dose or administration regimen for routine abdominal and pelvic CT; therefore, a Gastrografin-specific dilution, volume, and administration schedule cannot be established from this data. [2], [3], [4]

Relevant Prescribing Information

Indications And Usage [5]
Gastrografin may also be used as an adjunct to contrast enhancement in computed tomography of the torso (body imaging); the preparation is indicated, in conjunction with intravenous administration of a radiopaque contrast agent, when unenhanced imaging may not provide sufficient definition in distinguishing normal loops of bowel from adjacent organs or areas of suspected pathology.

Dosage and Administration [5]
Tomography (Body Imaging)
A usual adult dose is 240 mL of a dilute Gastrografin solution prepared by diluting 25 mL (9.17 g iodine) to one liter with tap water. Less dilute solutions [up to 77 mL (28.26 g iodine) diluted to one liter with tap water] may be used when indicated. The dose is administered orally about 15 to 30 minutes prior to imaging in order to permit the contrast medium to reach the pelvic loops.

Literature Review

A search of the published medical literature revealed 2 studies investigating the researchable question:

What alternatives can be used for oral contrast for CT since Omnipaque oral is not available. What is data on using Gastrograffin and how would it be dosed for this indication

Level of evidence

B - One high-quality study or multiple studies with limitations Read more→

Please see Tables 1-2 for your response.

Prospective Randomized Trial of Iohexol 350 Versus Meglumine Sodium Diatrizoate as an Oral Contrast Agent for Abdominopelvic Computed Tomography
Design	Prospective randomized trial N= 100
Objective	To compare the efficacy and patient tolerance of iohexol and meglumine sodium diatrizoate as oral contrast agents for computed tomography (CT)
Study Groups	Sodium diatrizoate (n= 51) Iohexol (n= 49)
Inclusion Criteria	Patients scheduled for abdominopelvic CT at the outpatient facility, aged 18 or older, not pregnant, no history of adverse reaction to iodinated oral or intravenous contrast, and no known or suspected small-bowel obstruction
Exclusion Criteria	Individuals younger than 18 years, pregnant women, patients with a history of adverse reaction to iodinated oral or intravenous contrast, or those with known or suspected small-bowel obstruction
Methods	A total of 100 patients undergoing abdominopelvic CT were randomized to receive diatrizoate (n=51) or iohexol (n=49). Each agent was diluted to an iodine concentration of 8 mg/mL (23 mL of Omnipaque 350 in 977 mL water or 22 mL of Gastroview in 978 mL water), and patients consumed 1,000 mL before CT. Taste was rated on a 1-10 scale, adverse effects were assessed by questionnaire and follow-up telephone call 1-3 days later, and two blinded radiologists rated gastrointestinal opacification extent and density on a 1-5 scale.
Duration	Not specified
Outcome Measures	Extent and density of bowel opacification
Baseline Characteristics		Sodium diatrizoate	Iohexol
	Sex (M/F)	20 (39%)/31 (61%)	23 (47%)/26 (53%)
	Ethnicity - Caucasian	48 (94%)	43 (88%)
	Ethnicity - African-American	2 (4%)	6 (12%)
	Ethnicity - Other	1 (2%)	0
	Mean age, yrs	52.4	51.6
Results	Patients' Reaction	Sodium diatrizoate	Iohexol
	Able to Finish Drinking	48 (94%)	47 (96%)
	Mean taste Rating	6.0	7.1
	Nausea (Mild)	4 (8%)	1 (2%)
	Vomiting	0	0
	Cramping	1 (2%)	0
	Bloating	1 (2%)	0
	Diarrhea	0	1 (2%)
	Had Contrast Before	47 (94%)	45 (92%)
	Previous CT at Barnes-Jewish Hospital	46 (92%)	41 (84%)
	Compare Taste to Last Time (better)	23 (50%)	30 (68%)
	Both oral contrast agents were well tolerated, with similar rates of reported adverse effects and no episodes of vomiting. Iohexol was rated more favorably for taste than diatrizoate (mean scores, 7.1 vs 6.0; p= 0.02). Gastrointestinal opacification was similar between agents, with no statistically significant differences in qualitative opacification extent and only one statistically significant difference in opacification density, favoring iohexol in the ileum for one reader (p= 0.01). Measured radiodensity was also similar across gastrointestinal segments, except for a small statistically significant difference in the ileum favoring iohexol.
Adverse Events	No statistically significant difference between the two agents in adverse effects. Mild nausea was reported by 4 patients with diatrizoate and 1 with iohexol. One patient reported cramping with diatrizoate, and one reported diarrhea with iohexol.
Study Author Conclusions	Iohexol 350 is a satisfactory oral contrast agent for abdominopelvic CT. It opacifies the gastrointestinal tract as well as meglumine sodium diatrizoate does, and patients prefer the taste of iohexol to that of diatrizoate.
Critique	The study's strengths include its randomized design and the use of blinded radiologists to assess outcomes, which reduces bias. However, the sample size is relatively small, which may limit the detection of statistically significant differences in adverse effects. Additionally, the study did not flavor the contrast agents, which may not reflect typical clinical practice where flavoring is often used to improve patient tolerance.

Table 1 References:
[6] Peterson CM, Lin M, Pilgram T, Heiken JP. Prospective randomized trial of iohexol 350 versus meglumine sodium diatrizoate as an oral contrast agent for abdominopelvic computed tomography. J Comput Assist Tomogr. 2011;35(2):202-205. doi:10.1097/RCT.0b013e3182058e76

Iopamidol as an oral contrast media for computed tomography: a taste comparison to iohexol, diatrizoate sodium, and barium sulfate
Design	Blinded and randomized trial N= 50
Objective	To compare the palatability of iopamidol and iohexol
Study Groups	Iopamidol (n= 50) Iohexol (n= 50) Gastrografin (n= 50) Barium sulfate (n= 50)
Inclusion Criteria	Healthy participants over the age of 18 years, approximately equally distributed in gender, recruited from the University Hospital radiology department
Exclusion Criteria	Pregnancy, aspiration risk, impaired taste or smell, known allergy to contrast media
Methods	Four oral contrast agents were evaluated for taste acceptability in 50 participants: iopamidol (24.6 mL of Isovue 370 in 975.4 mL sterile water), iohexol (30.3 mL of Omnipaque 300 in 969.7 mL sterile water), diatrizoate (24.8 mL of Gastrografin in 975.2 mL sterile water), and barium sulfate suspension (READI-CAT 2, 2.1% w/v, 2.0% w/w). The three water-soluble agents were diluted to a standardized iodine concentration of 9.1 g/L. Participants tasted all four agents in randomized order and rated acceptability on a 0-40 scale (0 = intolerable; 20 = neutral; 40 = strongly like).
Duration	Not specified
Outcome Measures	Palatability scores of contrast agents
Baseline Characteristics		All participants (n= 50)
	Gender distribution	Approximately equal
Results		Mean Score (SD/SEM)
	Iopamidol	21.0 (8.4/1.2)
	Iohexol	21.8 (7.1/1.0)
	Gastrografin	16.8 (9.6/1.4)
	Barium	23.7 (9.1/1.3)
Adverse Events	No adverse events reported, including no nausea or allergic reactions
Study Author Conclusions	There is no significant difference in palatability between iopamidol and iohexol, supporting the use of iopamidol as a viable alternative to iohexol as an oral contrast agent.
Critique	The study's strength lies in its randomized and blinded design, which minimizes bias. However, the use of healthy volunteers rather than a patient population may limit the applicability of the findings to clinical settings. Additionally, the small sample size and the tasting of small amounts rather than full CT protocol volumes may not fully represent patient experiences during actual procedures..

Table 2 References:
[7] Rogers D, Sheth C, Eisenmenger L, Mignogna E, Winter T. Iopamidol as an oral contrast media for computed tomography: a taste comparison to iohexol, diatrizoate sodium, and barium sulfate. Abdom Radiol (NY). 2017;42(12):2822-2826. doi:10.1007/s00261-017-1226-0